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Abstract 
Background: We aimed to investigate the mortality rate (MR), causes of death and standardized mortality ratio (SMR) 
in Korean type 2 diabetic patients from 2002 to 2013 using data from the Korean National Health Insurance Service‑
National Sample Cohort (NHIS‑NSC).
Methods: From this NHIS‑NSC, we identified 29,807 type 2 diabetic subjects from 2002 to 2004. Type 2 diabetes 
was defined as a current medication history of anti‑diabetic drugs and the presence of International Classification of 
Diseases (ICD)‑10 codes (E11–E14) as diagnosis. Specific causes of death were recorded according to ICD‑10 codes as 
the following: diabetes, malignant neoplasm, disease of the circulatory system, and other causes.
Results: A total of 7103 (23.8 %) deaths were recorded. The MR tended to increase with age. In particular, the ratio of 
MR for men versus women was the highest in their 40s–50s. The overall SMR was 2.32 and the SMRs attenuated with 
increasing age. The causes of death ascribed to diabetes, malignant neoplasm, ischemic heart disease, cerebrovascu‑
lar disease, and other causes were 22.0, 24.8, 6.2, 11.2 and 31.3 %, respectively. The SMRs according to each cause of 
death were 9.73, 1.76, 2.60, 2.04 and 1.89, respectively.
Conclusions: The MRs among type 2 diabetic subjects increased with age, and diabetic men exhibited a higher mor‑
tality risk than diabetic women in Korea. Subjects with type 2 diabetes exhibited an excess mortality when compared 
with the general population. Approximately 78.0 % of the diabetes‑related deaths was not ascribed to diabetes, and 
malignant neoplasm was the most common cause of death among those not recorded as diabetes.
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Background
Individuals with diabetes have higher all-cause mortality 
rates (MRs) compared to similar people without diabetes 
[1], primarily due to the development of cardiovascular 
disease (CVD) [2]. In fact, the increased mortality risk 
among patients with type 2 diabetes in Western countries 
has mainly been attributed to CVD [2]. Nevertheless, the 
extent of increase in the mortality risk might vary among 
the populations of different countries [3]. In particular, 
this scenario might differ in Asian and other developing 
regions of the world, whereby infection and renal failure 
have been the main causes of death in people with diabe-
tes [2]. In addition, evidence is also emerging that diabe-
tes is associated with nonvascular conditions, especially 
its positive association with certain types of cancer [4, 5].
Although data on diabetes-related mortality has been 
available in other races and ethnic groups [1, 2, 6, 7], 
there is a lack of data on diabetes-related mortality that 
is representative of Asian population; this is particularly 
true of Korea, where diabetes remains a major health 
problem, with a reported prevalence of 11.0  % in 2013 
[8]. A study using data from the Korea National Statis-
tical Office revealed that mortality ascribed to diabetes 
has increased 3.5-fold between 1983 and 2001, which is 
Open Access
Cardiovascular Diabetology
*Correspondence:  chjung0204@gmail.com 
†Yu Mi Kang and Ye‑Jee Kim equally contributed to this work 
1 Department of Internal Medicine, Asan Medical Center, University 
of Ulsan College of Medicine, 88, Olympic‑ro 43‑gil, Songpa‑gu, Seoul, 
South Korea
Full list of author information is available at the end of the article
Page 2 of 10Kang et al. Cardiovasc Diabetol  (2016) 15:131 
a marked increase compared to that of other developed 
countries, such as Japan, the United States and the United 
Kingdom over a similar time period (1985–2000) [9]. 
However, the causes of death ascribed to diabetes-related 
mortality were diverse and some were even non-specific 
[9]. Hence, it is vital to obtain detailed and accurate infor-
mation on the MRs and specific causes of death in the 
population of interest. Such knowledge could serve as a 
fundamental basis for establishing a national health plan, 
and could thereby minimize the diabetes-related hazards 
in public health in the long term.
Ideally, data should be randomly collected from unse-
lected populations to avoid selection bias. However, most 
previous studies on mortality in diabetic populations 
including Korean studies have been confined to a par-
ticular setting, either in the community [10], or hospi-
tals [2, 4, 11]. Although the data obtained from subjects 
in such limited settings can be easily recorded and han-
dled, the findings are not representative of the national 
diabetic population. Recently, Korean National Health 
Insurance Service-National Sample Cohort (NHIS-NSC), 
a population-based cohort derived from nearly all Korean 
citizens, was established with an aim towards providing 
public health researchers and policy makers with repre-
sentative, useful information regarding the utilization of 
health insurance and health examinations of the citizens 
[12].
In the present study, we aimed to obtain a reliable and 
comprehensive understanding of mortality in the Korean 
diabetic population by determining the MRs and causes 
of death from this national sample of Korea. Further-
more, we evaluated the excess mortality expressed as the 
standardized mortality ratio (SMR) in diabetic patients 
compared with that in the general population.
Methods
Study population
The NHIS was initiated in 1963 in Korea according to the 
National Health Insurance Act, and all Korean citizens 
were mandated to participate in this program [12]. Cur-
rently, the Korean NHIS maintains and manages all data-
bases of Korea’s health service utilization. The detailed 
structure and function of NHIS is described elsewhere 
[12].
In the present study, we used data from the NHIS-NSC 
2002–2013, which were released by the Korean NHIS in 
2014. The data comprise a nationally representative ran-
dom sample of 1,025,340 individuals, which accounts 
for approximately 2.2 % of the entire population in 2002 
[12]. The data were built by using probabilistic sampling 
to represent an individual’s total annual medical expenses 
within each of 1476 strata defined by age, sex, eligibility 
status (employed or self-employed), and income level (20 
quantiles for each eligibility status and medical-aid ben-
eficiary) combinations via proportional allocation from 
the 46,605,433 Korean residents in 2002 [12, 13]. The 
NHIS-NSC is a semi-dynamically constructed cohort 
database; the cohort has been followed up to either the 
time of the participant’s disqualification from receiving 
health services due to death or emigration or until the 
end of the study period, whereas samples of newborn 
infants are included annually [12, 13]. The database con-
tains eligibility and demographic information regarding 
health insurance as well as data on medical aid benefi-
ciaries, medical bill details, medical treatment, disease 
histories and prescriptions; such data were constructed 
after converting insurance claim information to the first 
day of medical treatment.
From this cohort, we selected subjects recorded to have 
type 2 diabetes between 2002 and 2004. Type 2 diabetes 
was defined if anti-diabetic drugs were prescribed and 
the 10th revision of International Statistical Classifica-
tion of Diseases, International Classification of Diseases 
(ICD)-10 codes E11 (non-insulin-dependent diabetes 
mellitus), E12 (malnutrition-related diabetes mellitus), 
E13 (other specified diabetes mellitus), or E14 (unspeci-
fied diabetes mellitus) was assigned as either principal 
or additional diagnosis. Antidiabetic drugs dispensed 
in the pharmacy during the study period in Korea con-
sisted of six classes (i.e., sulfonylureas, biguanide, alpha-
glucosidase inhibitor, thiazolidinediones, meglitinide and 
insulin) [14]. Incretin-based therapies (i.e. glucagon-like 
peptide -1 receptor agonists and dipeptidyl peptidase-4 
inhibitors) were not introduced during the study period.
This diabetic cohort was followed up from the index 
date until the end of the study period (i.e., December 31, 
2013), until the last year of qualification for those who 
were alive, or until the date of death for those who died. 
This study was approved by the NHIS inquiry commis-
sion. The personal privacy of each participant was pro-
tected by de-identification of the national insurance 
claims data for analysis. This study was also approved 
by the Institutional Review Board of the Asan Medical 
Center (IRB-No 2016-0149).
Mortality data and causes of death
Information on mortality and cause of death were avail-
able for all subjects in the cohort; the latter was classi-
fied according to the Korean Standard Classification of 
Diseases and Causes of Death [15], based on the ICD-
10, as provided by the Korean National Statistical Office. 
Diseases or conditions directly leading to death were 
adopted as the specific causes of death, and accordingly, 
they were classified as the following ICD-10 codes: malig-
nant neoplasm (C00-97), diabetes mellitus (E11-14), dis-
eases of the circulatory system (I00-99) and other causes 
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(codes other than those mentioned above). Among the 
deaths due to diseases of the circulatory system (I00-99), 
deaths due to ischemic heart diseases (I20-25), and cer-
ebrovascular diseases (I60-69) were further analyzed.
Statistical analysis
We calculated the MR in each age group- and sex- by 
using the number of deaths as the numerator and the 
sum of person-years during the study period as the 
denominator. The MR ratios and their 95  % confidence 
intervals (CIs) for men versus women in each age stratum 
were estimated by Cox proportional hazard models.
Standardization was applied to calculate the SMRs, and 
the observed deaths were divided by the expected deaths 
for each age stratum and sex. Expected deaths were com-
puted using the MR of the average of midyear population 
between 2002 and 2013, as reported by the Korean Sta-
tistical Information Service. (Statistics Korea. Causes of 
death statistics. 2002–2013) [16]. Byar’s approximation 
was used to calculate the 95 % CIs for the SMRs [17].
All statistical analyses were performed using SAS soft-
ware (version 9.4, SAS Institute, Inc., Cary, NC, USA).
Results
Of a total of 1,025,340 randomly selected individuals 
from the NHIS-NSC (comprising 2.2  % of the total eli-
gible Korean population in 2002), we identified 29,807 
diabetic individuals (15,625 men and 14,182 women) 
between 2002 and 2004 (Additional file 1: Table S1). Most 
of the enrolled subjects (70.3  %) were registered during 
the first year of this study. The NHIS database does not 
provide the exact age of each subject, but instead indi-
cate the ages by 18 age groups (infants aged <1 year, ages 
1–4  years, age groups with 5-year-intervals between 5 
and 79 years, and ≥80 years) [12]. The majority of sub-
jects (58.5 %) were in their 50s and 60s (Additional file 1: 
Table S1).
Over a total of 289,647.4 person-years of follow-up, 
7103 subjects (3980 men and 3123 women, Additional 
file  1: Table S1) died and the crude MR was 26.7 and 
22.2 per 1000 person-years in men and women, respec-
tively (Table 1). The age- and sex-specific MR and SMRs, 
as well as the MR ratios for men versus women in each 
age stratum are listed in Table 1. The MR in the diabetic 
subjects tended to increase with age, from 5.7 per 1000 
person-years in subjects aged 30–34  years to 153.6 per 
1000 person-years in those aged ≥80  years in men; the 
corresponding value changed from 3.6 to 124.4 per 1000 
person-years in women (Table  1). Furthermore, men 
with diabetes exhibited a higher risk of mortality (MR 
ratio: 1.21, 95 % CI 1.15–1.26; Table 1). The MR ratio for 
men versus women was highest in their early 40s (3.17, 
95  % CI 1.98–5.07; Table  1). However, this sex-related 
difference in mortality risk was attenuated by increasing 
age after 50 years of age (Table 1).
Excess mortality among the diabetic subjects, relative 
to the general population, can be represented by SMRs. 
The overall SMR was 2.32 (Table 2), and the SMRs were 
found to be attenuated in the elderly subjects (Table 1). 
The SMR was greater in women than in men across most 
age groups (Table 1).
The observed numbers and percentages of the specific 
causes of death, as well as the SMRs for all causes and 
each specific cause of death according to sex are shown in 
Table 2, Figs. 1 and 2. Approximately 78.0 % of the diabe-
tes-related deaths were not ascribed to diabetes in Korea. 
In fact, malignant neoplasm was the most common cause 
of death in this cohort (24.8  %, 6.1 per 1000 person-
years) followed by the diseases of the circulatory system 
and diabetes. In particular, malignant neoplasm was the 
most common cause of death among men with diabetes 
(29.6 %, 7.9 per 1000 person-years, Table 2; Fig. 1). Dis-
eases of the circulatory system were the most common 
cause of death among women with diabetes (26.0 %, 5.8 
per 1000 person-years, Table 2; Fig. 1). In both sexes, the 
proportion of mortality cases ascribed to cerebrovascular 
disease was greater than that ascribed to ischemic heart 
disease (Table  2; Fig.  1). Furthermore, regardless of the 
causes of death listed in Table 2, diabetic subjects exhib-
ited a significantly higher risk of mortality than the gen-
eral population, as demonstrated by the SMRs (Table 2; 
Fig.  2). The excess mortality ascribed to ischemic heart 
disease as demonstrated by the SMRs was the highest of 
all causes, except for diabetes (2.60; 95  % CI 2.37–2.86; 
Table 2; Fig. 2).
Discussion
This population-based cohort study provides a more 
accurate and less biased view of the issues regarding 
mortality in the Korean diabetic population. A compre-
hensive analysis of the MR, causes of death and SMR in 
subjects with type 2 diabetes, compared with those in 
the general population in Korea indicated that diabetic 
men had a higher mortality risk than diabetic women 
(Table 1). Moreover, diabetes was associated with excess 
mortality, which was primarily contributed by ischemic 
heart diseases, compared to that in the general popula-
tion (Table  2; Fig.  2). Among the cases of mortality not 
ascribed to diabetes, malignant neoplasm was the most 
common cause of death (Table 2; Fig. 1).
Whereas previous studies investigating ethnic differ-
ences in mortality and major diabetic complications have 
enrolled Asian–Americans and Asian–Europeans with 
heterogeneous Asian backgrounds for comparison [18], 
our study enrolled Korean diabetic population residing 
in Korea, reflecting the genetic and cultural influences 














































































































































































































































































































































































































































































































































































































































































































































Page 5 of 10Kang et al. Cardiovasc Diabetol  (2016) 15:131 
as well as the current features of Korean healthcare sys-
tem. Nonetheless, despite the expected disparities, our 
results share several common findings reported from 
previous studies that enrolled both similar [7] and dif-
ferent [6, 19] ethnicities. The MRs according to age and 
sex observed in the present study (Table 1) were similar 
Table 2 Overall number (percentage) of  deaths, mortality rates and  standardized mortality ratios in  specific causes 
deaths classified by ICD-10 codes
MR mortality rate (1000 person-years), SMR standardized mortality ratio, CI confidence interval
Causes of death Men Women Total
Deaths (%) MR SMR (95 % CI) Deaths (%) MR SMR (95 % CI) Deaths (%) MR SMR (95 % CI)
All cause 3980 (100) 26.7 2.20 (2.13–2.27) 3123 (100) 22.2 2.54 (2.45–2.63) 7103 (100) 24.5 2.32 (2.27–2.38)
Malignant neoplasm 1177 (29.6) 7.9 1.83 (1.73–1.94) 582 (18.6) 4.1 1.70 (1.57–1.85) 1759 (24.8) 6.1 1.76 (1.67–1.84)
Diabetes mellitus 787 (19.8) 5.3 9.48 (8.83–10.17) 773 (24.8) 5.5 10.03 (9.34–10.77) 1560 (22.0) 5.4 9.73 (9.25–10.23)
Diseases of the circulatory system 753 (18.9) 5.0 2.04 (1.90–2.19) 811 (26.0) 5.8 2.35 (2.19–2.52) 1564 (22.0) 5.4 2.18 (2.07–2.29)
Ischemic heart disease 227 (5.7) 1.5 2.35 (2.05–2.68) 212 (6.8) 1.5 2.96 (2.58–3.39) 439 (6.2) 1.5 2.60 (2.37–2.86)
Cerebrovascular disease 378 (9.5) 2.5 1.91 (1.72–2.11) 421 (13.5) 3.0 2.21 (2.00–2.43) 799 (11.2) 2.8 2.04 (1.90–2.19)
All other causes 1263 (31.7) 8.5 1.76 (1.67–1.86) 957 (30.6) 6.8 2.06 (1.94–2.20) 2220 (31.3) 7.7 1.89 (1.81–1.97)
Fig. 1 Overall mortality rates according to specific causes of death classified by ICD‑10 codes
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to those reported in previous population-based studies 
[6, 7]. For example, the MRs of diabetic patients in the 
US national cohort increased from 12.4 per 1000 per-
son-years in those aged 25–44  years at baseline to 89.7 
per 1000 person-years in those aged 65–74  years [6]. A 
study using the national sample of Taiwan also reported 
that the MR of diabetic patients increased from 14.1 per 
1000 person-years in patients aged <45 years to 86.3 per 
1000 person-years in those aged ≥75  years among dia-
betic men; and from 4.5 to 77.8 per 1000 person-years 
among diabetic women, respectively [7]. Similarly, the 
age-dependent increase in the MRs and the attenuation 
of the excess mortality (demonstrated by the SMRs) with 
increasing age (Table  1) were consistent with the find-
ings of previous population-based studies [6, 7, 19]. In 
particular, Swedish National Diabetes Register reported 
much higher excess risk of death among patients younger 
than 55  years of age, as compared with controls in the 
same age group, despite a glycemic profile within the 
target range and normoalbuminuria [19]. Collectively, 
these results suggest that, regardless of ethnicity and the 
degree of glycemic control, special attention should be 
paid to the management of type 2 diabetes in a younger 
population to further improve their mortality outcomes.
With respect to sex-related differences, the MRs were 
relatively higher in diabetic men than in diabetic women 
(overall 1.21; Table 1), consistent with the findings from 
other studies [6, 7, 20]. In contrast, the overall SMR was 
greater in women (2.54 [95 % CI, 2.45–2.63]) than in men 
(2.20 [2.13–2.27]; Table  1) in our study, which suggests 
that Korean women are more likely to be vulnerable to 
the malicious effects of diabetes as compared to Korean 
diabetic men, once they are diagnosed with it.
In our current study, we found that only 22  % of the 
subjects had diabetes mellitus coded as the primary 
cause of death on their death certificates (Table 2; Fig. 1). 
Although the direct cause of such diabetes-related death 
remains unclear, the findings of a national cohort study of 
Taiwan has provided an important clue [7]. In this study, 
the authors postulated that individuals with diabetes as 
the recorded cause of death are more likely to have died 
due to CVD than due to cancer, since it is much more 
plausible for clinicians to detect and code for cancer on 
the death certificate if the patient had died from cancer 
despite the co-existence of diabetes or its related compli-
cations [7]. Moreover, if we consider that the patients in 
the present study actually died due to CVD rather than 
diabetes, as reported, then the proportion of such sub-
jects would sum up to 44 %, which is similar to the values 
from other nationwide cohort studies [6, 7, 21]. Never-
theless, the limitations of mortality record-based studies 
should not be overlooked, and this issue requires further 
investigation.
Besides diabetes, malignant neoplasm (24.8  %) and 
diseases of the circulatory system (22.0  %) including 
ischemic heart diseases and cerebrovascular diseases 
were the two most common causes of death in both sexes 
(Table  2; Fig.  1). With regard to sex-related differences, 
we found that the most common cause of death was 
malignant neoplasm among diabetic men and diseases of 
the circulatory system among diabetic women (Table  2; 
Fig.  1). Similar trends were noted in a Taiwanese study 
[7], wherein the sum of percentages of deaths attributed 
to a composite of cardiopulmonary diseases, stroke, and 
disease of arteries, arterioles, and capillaries was greater 
than the percentages of deaths due to cancer in diabetic 
women, whereas the converse was true for diabetic men 
[7].
Epidemiologic evidence suggests that individuals with 
diabetes are at a significantly higher risk for many forms 
of cancer [5]. Moreover, findings from other observa-
tional studies indicate that some medications used to 
Fig. 2 Standardized mortality ratios according to specific causes of 
death classified by ICD‑10 codes
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treat hyperglycemia might also be associated with either 
an increased or reduced risk of cancer [22, 23]. The rela-
tive risks due to diabetes were greater (approximately 
twofold or higher) for malignant neoplasm of the liver, 
pancreas, and endometrium, and lower (approximately 
1.2- to 1.5-fold higher) for malignant neoplasm of the 
colon and rectum, breast, and bladder [23]. Among the 
deaths ascribed to malignant neoplasm in the present 
study, malignant neoplasm of the liver and intrahepatic 
bile ducts was the most common cause of death (5.1 %, 
1.2 per 1000 person-years; Supplementary Table S2). 
Despite the high prevalence of hepatitis B or C in Korea 
[24, 25], this finding further support that diabetes-related 
factors including steatosis, nonalcoholic fatty liver dis-
ease, and cirrhosis might also enhance the susceptibility 
to liver cancer [26]. With regard to SMRs, death due to 
malignant neoplasm of the pancreas showed the highest 
SMR, compared to that in the general population (2.59, 
95 % CI 2.19–3.05. Additional file 1: Table S2). The high 
MRs due to malignancy seen in our present study sup-
port the previous epidemiologic evidence regarding the 
increased risk of malignancy in people with diabetes [5]; 
this theory is also supported by the marked increases in 
cancer-related death (from 4.7 to 21.9 %) in Korean indi-
viduals with type 2 diabetes over the past 10 years [4].
As supported by numerous epidemiologic and pro-
spective studies, type 2 diabetes significantly increases 
the absolute risk of developing CVDs in both Western 
[27] and Asian [28] populations. In Western countries, 
CVD is the leading cause of death among individuals 
with diabetes, and the risk of atherosclerotic diseases is 
increased by two to threefold [2]. Likewise, the propor-
tion of deaths attributed to CVD among individuals with 
diabetes from the Asia-Pacific region was similar to that 
observed in other countries [2]. In particular, large-scale 
nationwide studies and multinational analyses have indi-
cated that, heart disease is a more common cause of 
death than stroke in most Western countries [7], whereas 
stroke is a more common cause of death in Asian coun-
tries [2]. In the present study, the MRs ascribed to cer-
ebrovascular diseases were greater than those ascribed to 
ischemic heart disease in both genders (Table 2; Fig. 1). 
This distinctive finding can be explained by the fact that, 
in Korea, stroke remains a major health burden and that 
the risk factors for stroke are highly prevalent [29]. For 
the period between 2001 and 2009, the rate of admis-
sion for stroke, including hemorrhagic stroke, as the 
primary diagnosis remained stable, whereas the admis-
sion rates for ischemic stroke substantially increased 
in Korea [29]. Moreover, based on a prospective cohort 
study performed in the 1990s and early 2000s, hyperten-
sion had the highest population attributable risk (PAR) 
for stroke, which was even greater than that for ischemic 
heart disease. On the contrary, diabetes had a relatively 
low PAR for stroke in the Korean population [29]. These 
findings suggest that this high prevalence of stroke and 
the relatively low level of contribution of diabetes to the 
risk of stroke in the Korean population might have led to 
the higher MR ascribed to cerebrovascular diseases than 
those ascribed to ischemic heart diseases (Table 2; Fig. 1).
A comparison of SMRs for the common cause of death 
in individuals with diabetes showed that diseases of the 
circulatory system including ischemic heart disease and 
cerebrovascular disease were a major contributor of 
excess mortality in the diabetic population, compared to 
that of the general population (Table 2; Fig. 2). In particu-
lar, Fig. 2 illustrates a greater excess mortality ascribed to 
CVD in women than in men with diabetes. Although the 
reason underlying this sex-related difference is unclear, 
a relative loss of protection from cardiovascular deaths 
among women with diabetes might be a possible cause, 
as a similar loss of cardiovascular advantage has been 
previously observed in data from the US and the United 
Kingdom [30]. In addition, among the causes other than 
malignant neoplasm, diabetes and diseases of the circula-
tory system, renal failure showed the greatest association 
with the excess MR (3.0 % with an SMR of 4.44 [95 % CI 
3.84–5.10]; Additional file 1: Table S3). Because reduced 
estimated glomerular filtration rate is a strong and inde-
pendent risk factor for death and CVD [31], this finding 
indicates that Koreans with diabetes have a higher risk of 
dying from severe renal disease or its related conditions, 
than the general population.
Multiple factors such as age, sex, body mass index, 
unhealthy metabolic profile including triglycerides lev-
els and impaired glucose tolerance state, and the exist-
ence of comorbidities are associated with mortality in 
patients with type 2 diabetes [32–36]. Among these, the 
association between treatment-related factors and mor-
tality in diabetic patients has been recently reported [37]. 
For example, the implementation of a multidisciplinary 
personalized intervention program was associated with 
lower CVD and all-cause mortality over 3-year follow-
up in diabetic patients in Hong Kong [37]. On the other 
hand, the use of chronic medications to treat diabetes 
and comorbidities was associated with higher micro-/
macrovascular event, hospitalization, and death risk [38]. 
Moreover, a recent meta-analysis revealed that diabetes 
mellitus, especially with the requirement of insulin treat-
ment was associated with significantly higher short and 
long-term adverse cardiovascular outcomes after percu-
taneous coronary intervention compared to those who 
were not on insulin therapy [39, 40]. Therefore, we per-
formed additional analyses to determine whether the use 
of insulin in our cohort led to worse mortality-related 
outcomes. Consequently, insulin users showed much 
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higher MRs and SMRs across all age groups, in both 
sexes (Additional file 1: Tables S4, S5). Direct complica-
tions from insulin administration such as weight gain or 
hypoglycemia might have contributed to higher mortality 
in this subpopulation; however, given that insulin therapy 
is generally administered 10–15  years after diagnosis 
[41], it is more plausible that the requirement of insulin 
therapy reflects the longer and severe duration of diabe-
tes [39]. Nevertheless, in line with previous findings, our 
results suggest that insulin treatment is associated with 
higher mortality in type 2 diabetic patients, and thus, 
prognosis should be assessed differently when managing 
diabetic patients on insulin therapy.
The major strengths of our present study are the utili-
zation of a large and national sample of diabetic patients 
and the use of national registry data that allowed for 
a comprehensive understanding and ascertainment of 
information on mortality. However, our analyses had 
several limitations of note. First, our study only included 
people with type 2 diabetes, and hence did not reflect 
information on mortality in people with type 1 diabe-
tes in Korea. However, a much greater proportion of 
the diabetic population is diagnosed with type 2 diabe-
tes in Korea, and thus, our results reflect the majority 
of Korean diabetic population [42, 43]. Second, as we 
defined type 2 diabetes based on the prescription of anti-
diabetic drugs as well as the presence of ICD-10 codes, 
type 2 diabetic patients being controlled with lifestyle (i.e. 
diet and exercise) modification and those who were undi-
agnosed prior to the analysis might have been misclas-
sified as not having diabetes. Therefore, it was unable to 
analyze the cause of death in this subpopulation. Third, 
the potentially underreported cases of death ascribed to 
diabetes and the misclassification of some causes of death 
might have interfered with a more precise analysis. Our 
findings showed that more than three quarters of the 
diabetes-related deaths would not be ascribed to diabe-
tes in Korea (Table 2; Fig. 1). However, any death certif-
icate-based mortality study [21] has certain limitations 
due to the difficulty in authenticating the cause of death 
[30, 44–46]; nevertheless, we attempted to overcome this 
limitation by assessing a large-scale, nationally repre-
sentative dataset. Lastly, we could not predict the severity 
of diabetes by serologic markers such as HbA1c because 
HbA1c screening is not included in the national health 
screening program in Korea. However, we additionally 
ran subgroup analysis of patients with and without the 
requirement of insulin therapy, to identify mortality-
related outcomes according to the severity of diabetes.
In conclusion, more than 75 % of the diabetes-related 
deaths in Korea were in fact recorded not to be ascribed 
to diabetes. Moreover, diabetic men have a higher mor-
tality risk than diabetic women, and diabetic patients 
have excess mortality compared to the general popula-
tion. Besides diabetes, malignant neoplasm was most 
common among all causes of death, and ischemic heart 
disease was primarily responsible for excess mortal-
ity in individuals with diabetes compared to the general 
Korean population. These findings highlight the poten-
tial benefits of controlling cardiovascular risk factors and 
cancer screening in the diabetic population in Korea. 
However, the fact that 31.3 % of death was attributed to 
other causes should also not be ignored. Further long-
term investigation of various outcomes in this population 
may help confirm such beneficial effects.
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